LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Închisă

SectorSănătate

1.07 5.94

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

0.96

Maxim

1.08

Indicatori cheie
By Trading Economics
Venit	1.8M -32M
Vânzări	-166K 1.7M
EPS	-0.27
Marjă de profit	-1,852.384
Angajați	181
EBITDA	7.9M -29M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+413.59% upside

Statistici piață
By TradingEconomics
Capitalizare de piață	-6.9M 119M
Deschiderea anterioară	-4.87
Închiderea anterioară	1.07

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

0.9101 / 1.14 Suport & Rezistență

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 dec. 2025, 23:21 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec. 2025, 23:14 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec. 2025, 22:01 UTC

Principalele dinamici ale pieței

Costco Wholesale Reports Higher Monthly Sales

3 dec. 2025, 21:38 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec. 2025, 23:10 UTC

Câștiguri

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec. 2025, 23:06 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec. 2025, 22:20 UTC

Câștiguri

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec. 2025, 22:19 UTC

Câștiguri

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec. 2025, 22:17 UTC

Câștiguri

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec. 2025, 22:16 UTC

Câștiguri

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec. 2025, 22:15 UTC

Câștiguri

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec. 2025, 22:10 UTC

Achiziții, Fuziuni, Preluări

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec. 2025, 22:09 UTC

Achiziții, Fuziuni, Preluări

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 dec. 2025, 21:49 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:23 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec. 2025, 21:19 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:06 UTC

Câștiguri

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec. 2025, 21:03 UTC

Câștiguri

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

413.59% sus

Prognoză pe 12 luni

Medie 5.29 USD 413.59%

Maxim 8 USD

Minim 2 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.